Evidence map›Paper›PMID 38923173›Full record

ArticleCancer science2024

Acquired copy number amplification at the MYC enhancer in human B-precursor acute lymphoblastic leukemia cell lines.

Atsushi Watanabe, Lu Wang, Tze King Tan, Kevin Y Urayama, Toshihiko Kizuki, Chiaki Komatsu, Keiko Kagami, Tamao Shinohara, Shin Kasai, Minori Tamai and 8 more

Abstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer science, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Atsushi WatanabeDepartment of Pediatrics, School of Medicine, University of Yamanashi, Yamanashi, Japan.ORCID https://orcid.org/0000-0002-4181-8111
Lu WangCancer Science Institute of Singapore, National University of Singapore, Singapore City, Singapore.
Tze King TanCancer Science Institute of Singapore, National University of Singapore, Singapore City, Singapore.
Kevin Y UrayamaDepartment of Social Medicine, National Center for Child Health and Development, Tokyo, Japan.
Toshihiko KizukiDepartment of Pediatrics, School of Medicine, University of Yamanashi, Yamanashi, Japan.
Chiaki KomatsuDepartment of Pediatrics, School of Medicine, University of Yamanashi, Yamanashi, Japan.
Keiko KagamiDepartment of Pediatrics, School of Medicine, University of Yamanashi, Yamanashi, Japan.
Tamao ShinoharaDepartment of Pediatrics, School of Medicine, University of Yamanashi, Yamanashi, Japan.
Shin KasaiDepartment of Pediatrics, School of Medicine, University of Yamanashi, Yamanashi, Japan.
Minori TamaiDepartment of Pediatrics, School of Medicine, University of Yamanashi, Yamanashi, Japan.
Daisuke HaramaDepartment of Pediatrics, School of Medicine, University of Yamanashi, Yamanashi, Japan.
Koshi AkahaneDepartment of Pediatrics, School of Medicine, University of Yamanashi, Yamanashi, Japan.ORCID https://orcid.org/0000-0001-8591-1281
Kumiko GoiDepartment of Pediatrics, School of Medicine, University of Yamanashi, Yamanashi, Japan.
Hiroaki GotoDivision of Hematology/Oncology, Kanagawa Children's Medical Center, Yokohama, Japan.ORCID https://orcid.org/0000-0001-6737-1509
Kazuhito SatouDepartment of Genome Medicine, National Center for Child Health and Development, Tokyo, Japan.
Tadashi KanameDepartment of Genome Medicine, National Center for Child Health and Development, Tokyo, Japan.ORCID https://orcid.org/0000-0003-0281-9610
Takaomi SandaCancer Science Institute of Singapore, National University of Singapore, Singapore City, Singapore.
Takeshi InukaiDepartment of Pediatrics, School of Medicine, University of Yamanashi, Yamanashi, Japan.

Funding

Japan Society for the Promotion of Science JP19H03615
6 · The paper itself

Abstract

Our study highlights the discovery of recurrent copy number alterations in noncoding regions, specifically blood enhancer cluster (BENC-CNA), in B-precursor acute lymphoblastic leukemia (BCP-ALL) cell lines. We demonstrate that BENC-CNA acts as a super-enhancer, driving MYC expression and possibly contributing to the immortalization and proliferative advantage of BCP-ALL cells in vitro.

Indexed as

DNA Copy Number VariationsEnhancer Elements, GeneticPrecursor B-Cell Lymphoblastic Leukemia-LymphomaProto-Oncogene Proteins c-mycCell Line, TumorGene AmplificationHumansMYC protein, humanProto-Oncogene Proteins c-myc

Identifiers

PMID38923173
PMCPMC11462929

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.